These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 27561289

  • 1. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.
    Clin J Am Soc Nephrol; 2016 Nov 07; 11(11):1989-1998. PubMed ID: 27561289
    [Abstract] [Full Text] [Related]

  • 2. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.
    Clin J Am Soc Nephrol; 2014 Feb 07; 9(2):344-53. PubMed ID: 24311704
    [Abstract] [Full Text] [Related]

  • 3. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):45-52. PubMed ID: 29025789
    [Abstract] [Full Text] [Related]

  • 4. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.
    BMJ Open; 2017 Aug 23; 7(8):e016528. PubMed ID: 28838895
    [Abstract] [Full Text] [Related]

  • 5. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA, Eisenga MF, van Ballegooijen AJ, Beulens JWJ, Vervloet MG, Navis G, Gansevoort RT, Bakker SJL, De Borst MH.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):121-128. PubMed ID: 32124925
    [Abstract] [Full Text] [Related]

  • 6. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.
    Clin J Am Soc Nephrol; 2012 May 01; 7(5):810-9. PubMed ID: 22362065
    [Abstract] [Full Text] [Related]

  • 7. Mineral metabolites and CKD progression in African Americans.
    Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M.
    J Am Soc Nephrol; 2013 Jan 01; 24(1):125-35. PubMed ID: 23243213
    [Abstract] [Full Text] [Related]

  • 8. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.
    Nephrol Dial Transplant; 2013 Feb 01; 28(2):352-9. PubMed ID: 23129826
    [Abstract] [Full Text] [Related]

  • 9. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C, Cheng C, Wang J, Zhang L, Purrunsing Y, Yang G, Zeng M, Huang H, Ren W, Ye Y, Ma H, Xing C, Wang N.
    Clin Nephrol; 2020 Feb 01; 93(2):65-76. PubMed ID: 31793871
    [Abstract] [Full Text] [Related]

  • 10. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.
    Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE.
    Clin J Am Soc Nephrol; 2012 May 01; 7(5):727-34. PubMed ID: 22383747
    [Abstract] [Full Text] [Related]

  • 11. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.
    Kidney Int; 2014 Aug 01; 86(2):407-13. PubMed ID: 24429404
    [Abstract] [Full Text] [Related]

  • 12. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE.
    Clin J Am Soc Nephrol; 2013 May 01; 8(5):781-6. PubMed ID: 23335040
    [Abstract] [Full Text] [Related]

  • 13. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C, Craven TE, Chonchol MB, Cheung AK, Sarnak MJ, Ambrosius WT, Killeen AA, Raphael KL, Bhatt UY, Chen J, Chertow GM, Freedman BI, Oparil S, Papademetriou V, Wall BM, Wright CB, Ix JH, Shlipak MG, SPRINT Research Group.
    Clin J Am Soc Nephrol; 2018 Dec 07; 13(12):1816-1824. PubMed ID: 30425104
    [Abstract] [Full Text] [Related]

  • 14. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.
    J Nephrol; 2015 Aug 07; 28(4):477-84. PubMed ID: 25700931
    [Abstract] [Full Text] [Related]

  • 15. Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Edmonston D, Fuchs MAA, Burke EJ, Isakova T, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.
    Am J Kidney Dis; 2024 Sep 07; 84(3):349-360.e1. PubMed ID: 38583756
    [Abstract] [Full Text] [Related]

  • 16. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.
    Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I.
    J Am Soc Nephrol; 2011 May 07; 22(5):956-66. PubMed ID: 21436289
    [Abstract] [Full Text] [Related]

  • 17. Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.
    Isakova T, Cai X, Lee J, Katz R, Cauley JA, Fried LF, Hoofnagle AN, Satterfield S, Harris TB, Shlipak MG, Sarnak MJ, Ix JH, Health ABC Study.
    J Bone Miner Res; 2016 Apr 07; 31(4):742-8. PubMed ID: 26590361
    [Abstract] [Full Text] [Related]

  • 18. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M.
    Kidney Int; 2011 Jun 07; 79(12):1370-8. PubMed ID: 21389978
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J, Kocełak P, Owczarek A, Bożentowicz-Wikarek M, Mossakowska M, Olszanecka-Glinianowicz M, Wiecek A.
    Nephrol Dial Transplant; 2014 Sep 07; 29(9):1757-63. PubMed ID: 24729016
    [Abstract] [Full Text] [Related]

  • 20. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.
    Seiler-Mussler S, Limbach AS, Emrich IE, Pickering JW, Roth HJ, Fliser D, Heine GH.
    Clin J Am Soc Nephrol; 2018 Apr 06; 13(4):569-576. PubMed ID: 29507005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.